616875-76-4

Upstream product

• 616874-66-9 1-[2-[4,4'-fluorobenzhydryloxy]ethyl]-4-(3-(4-nitrophenyl)-1-oxopropyl)piperazine 

Downstream Products

• 616874-76-1 11-bromoundecanoic acid (4-{3-[4-(2-(4,4'-fluorobenzhydryloxy)ethyl)piperazin-1-yl]propyl}phenyl)amide 
• 910295-53-3 11-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-undecanoic acid {4-[3-(4-{2-[bis-(4-fluoro-phenyl)-methoxy]-ethyl}-piperazin-1-yl)-propyl]-phenyl}-amide 
• 616875-77-5 thioacetic acid S-[10-(4-{3-[(4-(2-(4,4'-fluorobenzhydryloxy)ethyl)piperazin-1-yl)propyl]phenyl}carbamoyl)decyl] ester 
• 910295-54-4 11-amino-undecanoic acid {4-[3-(4-{2-[bis-(4-fluoro-phenyl)-methoxy]-ethyl}-piperazin-1-yl)-propyl]-phenyl}-amide 

Relevant academic research and scientific papers

The design and synthesis of novel derivatives of the dopamine uptake inhibitors GBR 12909 and GBR 12935. High-affinity dopaminergic ligands for conjugation with highly fluorescent cadmium selenide/zinc sulfide core/shell nanocrystals

There is a growing demand for compounds with very high affinities for the dopamine transporter protein (DAT) that can be conjugated to fluorescent markers such as cadmium selenide/zinc sulfide core/shell nanocrystals. This paper describes the design and synthesis of two derivatives of the DAT antagonists GBR 12935 and GBR 12909. These compounds have a high biological affinity for DAT and may be conjugated to nanocrystals via a thiol linkage without a significant reduction in their biological activity. Such conjugates may be used in fluorescent imaging studies.